CD8A and breast carcinoma: Therefore, this trial will be the first study to provide valuable clinical data of the impact of everolimus on several important peripheral blood immune cells, including CD4+ T cells, CD8+ T cells, Ths, Tregs, and NK cells in patients with breast cancer.